Skip to main content

irbesartan

Generic: IRBESARTAN·Brand: AVAPRO, Avalide, Avapro, IRBESARTAN

irbesartan: 4 clinical trials tracked.

irbesartan evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about irbesartan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trials (4)

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy

NCT03762850·Phase 3·TVTX
Active, not recruiting

Primary endpoint: Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36

InterventionalRandomizedquadruple406 enrolledStarted 2018-12Completion 2026-0750 sites · Australia, United StatesTravere Therapeutics, Inc.

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS

NCT03493685·Phase 3·TVTX
Completed

Primary endpoint: Slope of Estimated Glomerular Filtration Rate (eGFR)

InterventionalRandomizeddouble371 enrolledStarted 2018-04Completion 2026-0350 sites · United StatesTravere Therapeutics, Inc.

Efficacy and Safety of Sparsentan (RE-021), a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study

NCT01613118·Phase 2·TVTX
Completed

Primary endpoint: Percent Change in Urine Protein/Creatinine (Up/C)

InterventionalRandomizeddouble109 enrolledStarted 2014-03Completion 2024-0333 sites · Czechia, Italy, United StatesTravere Therapeutics, Inc.

Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C

NCT00265642·Phase 3
Completed

Primary endpoint: Assessment of liver fibrosis changes by measurement of area of porto-septal fibrosis (morphometry)at M24

InterventionalRandomizeddouble166 enrolledStarted 2006-10Completion 2013-111 site · FranceANRS, Emerging Infectious Diseases